Multiple Myeloma Coverage from Every Angle

Recent News

Early Research Findings on Novel Bispecific Monoclonal Antibody in Resistant Myeloma
Racial/Ethnic Differences in Patients With Myeloma: Clonal Hematopoiesis, Tumor Markers, and Outcomes
Phase III GMMG-HD7 Trial: Isatuximab-Based Therapy for Newly Diagnosed Myeloma
Activating T Cells With Talquetamab to Treat Multiple Myeloma
Extended Follow-up With Daratumumab-Based Regimen in Newly Diagnosed Myeloma
First-in-Class Targeted Cellular Therapy Under Study in Resistant Multiple Myeloma
ASH 2021: Novel BCMA-Targeting Bispecific Antibody Under Study in Resistant Myeloma
ASH 2021: Bispecific Antibody Teclistamab in Early-Phase Myeloma Study
ASH 2021: Novel Immunocytokine Under Study in Resistant Multiple Myeloma
ASH 2021: Early-Phase Trial of Idecabtagene Vicleucel in Resistant Multiple Myeloma
ASH 2021: Combination Iberdomide and Dexamethasone for Resistant Multiple Myeloma
FDA Approves Daratumumab Combination Therapy for Multiple Myeloma
Is Induction With Lenalidomide-Based Therapy Plus Tandem ASCT of Benefit in Multihit Myeloma?
SITC 2021: Engineered Toxin Body Under Study in Resistant Multiple Myeloma
Novel Antibody-Drug Conjugate Under Study in Combination Therapy for Resistant Myeloma
Front-Line Daratumumab Triplet: Updated Overall Survival Results From MAIA
Can Adding E-Selectin Antagonist to Chemotherapy Improve Outcomes in AML?
Can a Novel Triplet Regimen Prevent Disease Progression in Patients With High-Risk Smoldering Myeloma?
Is There a Role for Consolidation Treatment in Newly Diagnosed Patients With Multiple Myeloma?
ASTRO 2021: Use of Radiotherapy in Palliation of Multiple Myeloma Bone Lesions
Melphalan Flufenamide Is Withdrawn as Myeloma Treatment From U.S Markets
Early and Late Relapse in Myeloma: Navigating the Complex Treatment Waters
Long-Term Strategy Required for Newly Diagnosed Multiple Myeloma
Is the COVID-19 mRNA Vaccine Effective in Patients With Multiple Myeloma?
Chemotherapy for Newly Diagnosed Myeloma in Low-Income Setting: Long-Term Findings
COVID-19 and Multiple Myeloma: Patient Questionnaire Findings From the UK
Salvage Autologous HSCT for Relapsed Myeloma: From the Polish Myeloma Study Group
SOHO 2021: Preclinical Look at Myeloma Cell Viability With Metformin Plus Lenalidomide
SOHO 2021: Does Prolonged Lenalidomide Maintenance Improve Survival After Transplant in Myeloma?
SOHO 2021: Update on BCMA-Directed CAR T-Cell Therapy for Resistant Myeloma
SOHO 2021: ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma
SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma
DREAMM-2: Sustained Activity Reported With Belantamab Mafodotin-blmf in Resistant Myeloma
Bone-Directed Therapy in Myeloma: How Often Should Bisphosphonates Be Given?
COVID-19 and Novel Agents for Myeloma: From a Single Center in the Czech Republic
Relapse-Associated Genetic Alterations and Drug-Specific Resistance in Myeloma
FDA Brief: Orphan Drug Designation for Two Novel Multiple Myeloma Treatments
COVID-19 Vaccine Responses Among Patients With Multiple Myeloma
Initial Results From Cohort A of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Myeloma
ICARIA-MM: Updated Results With Isatuximab-Based Therapy for Resistant Myeloma
BOSTON Trial: Survival Outcomes With Selinexor in Elderly Patients With Multiple Myeloma
Trends in Multiple Myeloma–Related Inpatient Mortality
Can an MRD-Adaptive Study Design Help to De-escalate Therapy for Multiple Myeloma?
Comparing Two Oral Doublet Regimens for Resistant Multiple Myeloma
FDA Issues Safety Alert for Use of Melphalan Flufenamide in Multiple Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.